KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Issued (2016 - 2025)

Jazz Pharmaceuticals has reported Shares Issued over the past 16 years, most recently at $85.2 million for Q4 2025.

  • Quarterly Shares Issued rose 826.34% to $85.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.9 million through Dec 2025, up 422.41% year-over-year, with the annual reading at $107.9 million for FY2025, 422.41% up from the prior year.
  • Shares Issued was $85.2 million for Q4 2025 at Jazz Pharmaceuticals, up from $733000.0 in the prior quarter.
  • Over five years, Shares Issued peaked at $85.2 million in Q4 2025 and troughed at $17000.0 in Q3 2024.
  • The 5-year median for Shares Issued is $13.1 million (2021), against an average of $20.4 million.
  • Biggest five-year swings in Shares Issued: plummeted 99.69% in 2024 and later skyrocketed 4211.76% in 2025.
  • Tracing JAZZ's Shares Issued over 5 years: stood at $18.2 million in 2021, then skyrocketed by 66.15% to $30.2 million in 2022, then plummeted by 70.64% to $8.9 million in 2023, then increased by 3.87% to $9.2 million in 2024, then soared by 826.34% to $85.2 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $85.2 million, $733000.0, and $10.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.